The glucagon-like peptide 1 receptor (GLP1R) is a therapeutic target for diabetes due to its involvement in insulin release through stimulation of the adenyl cyclase [37], with several GLP1 agonists currently in clinical use. This evidence concerns the gene GLP1R and diabetes mellitus.